Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).

Campbell, E. H., Elston, D. M., Hawthorne, J. D., & Beckert, D. R. (2019). Diagnosis and management of delusional parasitosis. Journal of the American Academy of Dermatology, 80(5), 1428–1434.

Carbon, M., & Correll, C. U. (2014). Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia. CNS spectrums, 19(S1), 35–53.

Caroff, S. N., & Campbell, E. C. (2016). Drug-induced extrapyramidal disturbances: Implications for contemporary practice. Psychiatric Clinics, 39(3), 391–411.

Dhaliwal, K., & Hirst, S. (2016). Caring in correctional nursing: A systematic search and narrative synthesis. Journal of Forensic Nursing, 12(1), 5–12.

Doyle, B. B. (2015). Stahl’s essential psychopharmacology: Prescriber’s guide. The Journal of Clinical Psychiatry, 76(5), 1964.

Gaynes, B. N., Brown, C. L., Lux, L. J., Brownley, K. A., Van Dorn, R. A., Edlund, M. J., Coker-Schwimmer, E., Weber, R. P., Sheitman, B., Zarzar, T., Viswanathan, M., & Lohr, K. N. (2017). Preventing and de-escalating aggressive behavior among adult psychiatric patients: A systematic review of the evidence. Psychiatric Services, 68(8), 819–831.

George, M., Maheshwari, S., Chandran, S., Manohar, J. S., & Sathyanarayana Rao, T. S. (2017, October-December). Understanding the schizophrenia prodrome. Indian J Psychiatry, 59(4), 505–509.

Habibi, R., Sirati Nayer, M., & Khaghanizade, M. (2015). Educational needs of families of patients with schizophrenia: A literature review. International Journal of Medical Reviews 2(2), 250–255.

Healthline. (2024a). What do you want to know about schizophrenia?

Healthline. (2024b). What you need to know about catatonia.

Hitczenko, K., Mittal, V. A., & Goldrick, M. (2021). Understanding language abnormalities and associated clinical markers in psychosis: The promise of computational methods. Schizophrenia Bulletin, 47(2), 344–362.

Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. The Lancet Psychiatry, 4(4), 295–301.

Imamura, A., Morimoto, Y., Ono, S., Kurotaki, N., Kanegae, S., Yamamoto, N., Kinoshita, H., Tsujita, T., Okazaki, Y., & Ozawa, H. (2020). Genetic and environmental factors of schizophrenia and autism spectrum disorder: Insights from twin studies. Journal of Neural Transmission, 127, 1501–1515.

Immonen, J., Jääskeläinen, E., Korpela, H., & Miettunen, J. (2017). Age at onset and the outcomes of schizophrenia: A systematic review and meta‐analysis. Early Intervention in Psychiatry, 11(6), 453–460.

Jadhav, B. S., Shah, B., Dhavale, H., Sharma, P. (2014). Delusional disorder: prevalence, clinical correlates and comorbidity. Andhra Pradesh Journal of Psychological Medicine, 15(1), 99–102.

Jalali Roudsari, M., Chun, J., & Manschreck, T. C. (2015). Current treatments for delusional disorder. Current Treatment Options in Psychiatry, 2(2), 151–167.

Kadakia, A., Catillon, M., Fan, Q., Williams, G. R., Marden, J. R., Anderson, A., Kirson, N., & Dembek, C. (2022). The economic burden of schizophrenia in the United States. The Journal of Clinical Psychiatry, 83(6), 43278.

Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., Hong, S.-H., & (Systematic Review). (2020). The American Psychiatric Association practice guideline for the treatment of clients with schizophrenia. American Journal of Psychiatry, 177(9), 868–872.

Kopera, M., Suszek, H., Bonar, E., Myszka, M., Gmaj, B., Ilgen, M., & Wojnar, M. (2015). Evaluating explicit and implicit stigma of mental illness in mental health professionals and medical students. Community Mental Health Journal, 51, 628–634.

Lecomte, T., Potvin, S., Samson, C., Francoeur, A., Hache-Labelle, C., Gagné, S., Boucher, J., Bouchard, M., & Mueser, K. T. (2019). Predicting and preventing symptom onset and relapse in schizophrenia—A metareview of current empirical evidence. Journal of Abnormal Psychology, 128(8), 840.

Lecturio Medical. (n.d.). Schizophrenia: Assessment – Psychiatry.

Li, R., Ma, X., Wang, G., Yang, J., & Wang, C. (2016, September). Why sex differences in schizophrenia? J Transl Neurosci, 1(1), 37–42.

Liu, C. H., Keshavan, M. S., Tronick, E., & Seidman, L. J. (2015). Perinatal risks and childhood premorbid indicators of later psychosis: Next steps for early psychosocial interventions. Schizophrenia Bulletin, 41(4), 801–816.

Mayo Clinic. (2020). Schizophrenia.

Modi, S., Dharaiya, D., Schultz, L., & Varelas, P. (2016). Neuroleptic malignant disturbance: Complications, outcomes, and mortality. Neurocritical Care, 24, 97–103.

Mojtabai, R., Fochtmann, L., & Bromet, E. (2017). Other psychotic disorders. In: B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), Kaplan & Sadock’s comprehensive textbook of psychiatry (pp. 3616–3667). Wolters Kluwer.

National Library of Medicine. (2016). First-generation versus second-generation antipsychotics in adults: Comparative effectiveness [Internet].

Patel, V., Simunyu, E., & Gwanzura, F. (1995). Kufungisisa (thinking too much): A Shona idiom for non-psychotic mental illness. The Central African Journal of Medicine, 41(7), 209–215.

Pinna, F., Sanna, L., Perra, V., Randaccio, R. P., Diana, E., Carpiniello, B., & Cagliari Recovery Study Group. (2014). Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia? Rivista di Psichiatria, 49(1), 41–49.

QSEN Institute. (n.d.) QSEN Competencies.

Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Wachtel, L. E., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zndi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369.

Sariah, A. E., Outwater, A. H., & Malima, K. I. (2014). Risk and protective factors for relapse among individuals with schizophrenia: A qualitative study in Dar es Salaam, Tanzania. BMC Psychiatry, 14(1), 1–12.

Seeman, M. V. (2016). Erotomania and recommendations for treatment. Psychiatric Quarterly, 87(2), 355–364.

St Clair, D., & Lang, B. (2021). Schizophrenia: A classic battle ground of nature versus nurture debate. Science Bulletin, 66(10), 1037–1046.

Startup, H., Pugh, K., Dunn, G., Cordwell, J., Mander, H., Černis, E., Wingham, G., Shirvell, K., Kingdon, D., & Freeman, D. (2016). Worry processes in patients with persecutory delusions. British Journal of Clinical Psychology, 55(4), 387–400.

Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O’Donnell, P., Cuenod, M., & Do, K. Q. (2016). Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? Schizophrenia Research, 176(1), 41–51.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). About criminal and juvenile justice.

Vieta, E., Garriga, M., Cardete, L., Bernardo, M., Lombraña, M., Blanch, J., Catalán, R., Vásquez, M., Soler, V., Ortuño, N., & Martínez, Arán, A. (2017). Protocol for the management of psychiatric patients with psychomotor agitation. BMC Psychiatry, 17(328).

Waller, H., Emsley, R., Freeman, D., Bebbington, P., Dunn, G., Fowler, D., Hardy, A., Kuipers, E., & Garety, P. (2015). Thinking well: A randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs. Journal of Behavior Therapy and Experimental Psychiatry, 48, 82–89.

Ware, M. R., Feller, D. B., & Hall, K. L. (2018). Neuroleptic malignant disturbance: Diagnosis and management. The Primary Care Companion for CNS Disorders, 20(1), 27030.

World Health Organization. (2022). Schizophrenia.

Young, S. L., Taylor, M., & Lawrie, S. M. (2014). “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of Psychopharmacology, 29(4), 353–362.


This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at
Citation information

© Jun 12, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.